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Abstract 
 
The objective of this work is to evaluate the binding mechanisms of synthetic cadherin peptides (ADTC7, 
ADTC9 and cHAVc3) to the EC1 domain of human E-cadherin. The binding sites of these peptides to the 
EC1 domain were determined by titrating the 
15
N-labeled EC1 domain with each peptide. The changes in 
the 
1
H,
15
N-HSQC NMR spectra were observed upon peptide titration. The AutoDock Vina molecular 
modeling program was also used to predict the binding sites of each cadherin peptide on the EC1 domain. 
NMR data confirmed that there are three potential binding sites of ADTC7 on the EC1 domain; these 
binding sites are around residues I53/V48, D103, and G115. The two potential binding sites of ADTC9 
peptide are around I4 and I53/V48 residues of EC1. The NMR data showed that ADTC7 peptide has 
higher binding affinity to the EC1 domain than ADTC9 peptide. For cHAVc3, it binds selectively to at 
the D103 residue on EC1. AutoDock Vina studies confirm some of the binding sites found by NMR 
studies. In the future, a more detail study will be conducted to evaluate the effect of peptide binding on 
the dynamics properties of the EC1 domain. 
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1. Introduction 
Cadherins are a large family of calcium-dependent adhesion molecules found in different 
tissues and in biological barriers such as the blood brain barrier (BBB) and intestinal mucosa [1]. 
They comprise at least five major subfamilies, which include type I classical cadherins, closely 
related type II cadherins, desmosomal cadherins (desmocollins and desmogleins), 
protocadherins, and a variety of cadherin-related molecules [2, 3]. E-cadherin is a type I cadherin 
found in epithelial tissues [2, 4, 5].  VE-cadherin is also found in endothelial cells and both E- 
and VE-cadherins are found in the microvessel endothelial cells of the blood-brain barrier [6]. E-
cadherin-mediated reaggregation of bovine brain microvessel endothelial cells (BBMEC) can be 
inhibited by anti-E-cadherin antibody [6], suggesting the presence of E-cadherin in BBMEC. It 
has been indicated that endothelial cells in the brain are the tightest in the body while endothelial 
cells in bone marrow are more loose [7]. E-cadherin consists of a cytoplasmic tail, which 
contains the juxta-membrane domain (JMD) and catenin-binding domain (CBD), a trans-
membrane region (T), and an extracellular region consisting of five repeated domains called 
EC1–5 [8]. EC1 and EC2 are important for cell-cell adhesion [9-11]. E- and VE-cadherins are 
responsible for cell-cell adhesion in the intercellular junctions of the BBB [12, 13]. The 
intercellular junctions contain three major parts: 1) zonula occludens (tight junctions), 2) zonula 
adherens (adheren junctions), and 3) macula adherens (desmosomes). E- and VE-cadherins are 
located in the adherens junctions [14]. Removal of calcium from the extracellular region of E- 
and VE-cadherins can loosen the intercellular junction of the cells [15, 16].  
One of the major problems in treating brain disorders such as tumors and Alzheimer’s and 
Parkinson’s diseases is the difficulty in delivering drugs to the brain; this is due to the existence 
of the BBB [17]. Drugs cannot readily penetrate through the BBB via transcellular or 
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paracellular pathways. Drug penetration through the transcellular pathway occurs via partition of 
the drug into the cell membranes; thus, the membrane partition is influenced by the 
physicochemical properties of the drug.  In addition, the presence of efflux pumps (e.g., P-
glycoprotein (Pgp)) prevents the drug from crossing the transcellular pathway of the BBB. 
Alternatively, the drug can penetrate using the paracellular pathway; however, drug penetration 
through this pathway is limited by the presence of the tight junctions of the BBB [18, 19]. These 
normally restrict the crossing of hydrophilic molecules with a molecular weight higher than 180 
Da [20].  
The binding between the complex of natural killer cell receptor KLRG1 and the EC1 domain 
of E-cadherin has been determined using X-ray crystallography and residue mutation 
experiments [21]. Solution NMR and X-ray crystallography of ECAD12 were studied to evaluate 
the binding activity of the N-terminus of E-cadherin. At low protein concentration, 
intramolecular binding of tryptophan-2 (W2) side-chain into the W2 pocket on the same 
molecule was detected via chemical shift changes. However, at high protein concentration, the 
X-ray structure indicates that two molecules of ECAD12 form a dimer using intermolecular 
exchange of W2 side-chains that are docked to the W2-binding pockets of the opposite 
molecules [22]. 
Interactions of cadherins with proteins in the cytoplasmic domain are important for the 
structural stability and cell-cell adhesion properties of cadherins on the cell surface. For example, 
the complex of P120 catenin and cadherin contributes to cadherin surface stability and its role in 
cell-cell adhesion. The crystal structure of P120 with the JMD core region of E-cadherin has 
been shown using NMR, and this study confirms that P120 regulates the stability of cadherin-
mediated cell-cell adhesion by binding to the majority of the JMD region [23]. 
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Our group has found that cadherin peptides can modulate the intercellular junctions of the 
BBB to improve drug delivery into the brain. His-Ala-Val (HAV) and Ala-Asp-Thr (ADT) 
peptides derived from the EC1 domain can modify the porosity of the intercellular junctions of 
Madin-Darby canine kidney (MDCK) cell monolayers [24, 25]. These peptides lower the 
transepithelial electrical resistance (TEER) and enhance permeation of a paracellular marker 
molecule (i.e., 
14
C- mannitol) and an anticancer drug (
3
H-daunomycin) through the BBB in an in 
situ perfused rat brain [26]. Recently, HAV- and ADT-peptides have been shown to improve the 
in vivo brain delivery of marker molecules (i.e., R800 near-IR dye and gadopentetic acid) into 
the brain [27]. Binding studies of EC5 with HAV and BLG4 peptides were conducted, and the 
structural characteristics of EC5 were determined via NMR, CD, FTIR, and docking molecular 
modeling [19].  
 
Table 1. Peptides used in the binding studies to the EC1 domain of E-cadherin 
Peptide Name Peptide Sequence Molecular Weight (Da) 
ADTC5 Cyclo(1,7)Ac-CDTPPVC-NH2 744 
ADTC7 Cyclo(1,7)Ac-CDTPPEC-NH2 802.89 
ADTC9 Cyclo(1,7)Ac-CDTPPYC-NH2 836.95 
HAVc3 Cyclo(1,6)Ac-CSHAVC-NH2 657 
HAV6 Ac-SHAVSS-NH2 627.66 
 
The objective of this work was to study the mechanism(s) through which peptides are able to 
modulate the paracellular pathway. The hypothesis is that the peptide activity is due to its 
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binding to the extracellular domain of E-cadherin. To confirm this, the potential binding sites of 
cyclic peptides on the EC1 domain of E-cadherin were investigated using 2D-NMR and 
molecular AutoDock program.  Previously, the physical stability of the EC1 domain under 
different conditions (e.g., pH, temperature, ionic strengths, and buffer) was studied using CD, 
UV, and fluorescence spectroscopies [28]. The physical stability of EC1 can be improved by 
alkylation of the only cysteine residue on the EC1 domain [28].  The alkylation prevents the 
formation of a covalent dimer via an intermolecular disulfide bond of the cysteine residue on 
EC1. Recently, the NMR assignments of the amino acids within the human EC1 domain of E-
cadherin have been completed using multidimensional 
1
H, 
15
N, and 
13
C NMR spectra [29]. Using 
these assignments, the binding sites of several E-cadherin cyclic peptides such as ADTC7, 
ADTC9, and HAVc3 (Table 1) were determined.  In this case, the 
15
N-labeled EC1 was titrated 
with cyclic peptides at different concentrations, the chemical shift changes at different residues 
were observed, and the magnitudes of the changes were determined as the overall chemical shift 
changes (ΔF). The chemical shift changes (ΔF) at a certain residue were plotted against peptide 
concentrations to calculate the dissociation constants (Kd) of the peptide on a site on the EC1 
domain. Molecular docking experiments were used to build working models for the most 
probable binding site(s) of each peptide on the EC1 domain of E-cadherin.  
 
2. Materials and Methods 
2.1. Transformation of pASK-IBA6-EC1 DNA into BL21 cells  
BL21 cells and plasmid cDNA vector were removed from –80°C and –20°C freezers, 
respectively, and thawed to 0°C on ice. The cDNA vector (1.0 L) was added into 50 L cells, 
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and the mixture was incubated for 30 min on ice. Then, the cells were placed in a 42°C water 
bath for 30 sec followed by immediate transfer into ice for 3 min; this process was repeated 
several times to induce heat shock for permeation of the cDNA vector. Under sterile condit ions, 
200 L of SOC medium (1.55 g yeast, 0.25 mL of 1 M KCl, 0.5 mL of 1 M MgCl2, 0.5 mL of 1 
M MgSO4, 1 mL of 1 M glucose in distilled H2O) was added to each mini tube containing cells 
and plasmid cDNA vector, and the cells were agitated at 250 rpm for 1 h at 37°C. The culture 
tubes were removed from the shaker, and 50 L and 150 L of cells, respectively, were 
incubated into two agar plates. The agar-containing cells were placed in a standing incubating 
chamber to grow for 12–16 h. Next, the plates were taken from the incubation chamber, and each 
colony in the plate was picked up with a pipette tip and transferred into a 50 mL tube containing 
10 mL of LB medium and 10 L of ampicillin antibiotic (1000x). The cells in the tube were 
incubated in the shaker incubator overnight (12–16 h) at 250 rpm and 37°C. These cells were 
used as starter cells to produce the non-labeled and 
15
N-labled EC1 protein (see below). 
 
2.2. Expression of 
15
N-labled EC1 protein using E. coli cells in M9 minimal medium 
To obtain the 
15
N-labled EC1 domain, the starter culture from the  overnight incubation was 
added to a 1 L flask containing 250 mL of M9 minimal medium (34 g of Na2HPO4, 15 g of 
KH2PO4, and 2.5 g of NaCl supplemented with 5 g of 
15
N-labled ammonium chloride 
(
15
NH4Cl)). The cell growth was monitored at OD550, and 24 μL of anhydrotetracycline (2 
mg/mL; Promega Inc., Madison, WI) was added to induce protein expression after the culture 
reached an OD of 0.5–0.6. This process usually takes about 3–5 h. The cells were incubated at 
30°C for 6 h and then harvested by centrifugation at 4500 × g to produce cell pellets, which were 
stored at –80°C. 
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2.3. Expression of non-labeled EC1 protein using E. coli cells in LB medium 
To obtain the non-labeled EC1 domain, the starter culture was added to a 1 L flask 
containing 250 mL of LB medium and 250 μL of ampicillin antibiotic (1000×). The cell growth 
was monitored at OD550, and 24 μL of anhydrotetracycline (2mg/ml; Promega Inc.) was added to 
induce protein expression after the culture reached an OD of 0.5–0.6. This process usually takes 
about 2–3 h. Then, the cells were incubated at 30°C for 6 h, after which time they were harvested 
by centrifuge at 4500 × g. The resulting cell pellets were stored at –80°C until further use. 
 
2.4. Purification of the EC1 protein 
The 
15
N-labeled and non-labeled EC1 were isolated from E. coli cells after lysing the cells by 
French press at 20,000 psi in 15 mL of binding buffer (buffer B) (100 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, and 0.02% NaN3) at pH 8.0. The cellular debris was removed by 
centrifugation at 21,000 × g at 4°C for 1 h. The supernatant containing soluble EC1 was added 
into an equal volume of buffer B. The mixture was centrifuged at 4,500 rpm for 20 min at 4°C in 
an Amicon Ultra concentrator (EMD Millipore, Billerica, MA) with a 10 kDa molecular weight 
cut-off. The concentrated protein solution was added into a StrepTactin II affinity column (size 
5.0 × 0.6 cm, GE Healthcare) equilibrated with buffer B at room temperature. The column was 
washed with buffer B to remove the unbound proteins. To isolate the desired EC1 protein, the 
column was eluted (flowrate 2 mL/min) with elution buffer (buffer E containing 100 mM Tris-
HCl, 150 mM NaCl, 1 mM EDTA, 0.02% NaN3, 2.5 mM desthiobiotin, and 1 mM DTT) at pH 
8.0. The purity of each fraction of EC1 was determined using 4–12% Tris-Bis SDS-PAGE. The 
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fractions of eluted protein were pooled and concentrated to 1.5 mL using an Amicon Ultra 
concentrator. The quantity of protein was determined using a UV spectrometer with molar 
absorption coefficient of 19,480 M
-1
 cm
-1 
as calculated from the composition of tryptophan and 
tyrosine residues at 280 nm. The final pure EC1 was stored in buffer E at 4°C. 
 
2.6. NMR experiments 
The 2D 
1
H-
15
N HSQC experiments were performed on a Bruker Avance 600 MHz NMR 
spectrometer equipped with a triple resonance probe. The spectra were acquired in 16 scans with 
2048 points in 
1
H resonance and 128 increments in 
15
N resonance. An internal standard (4,4-
dimethyl-4-silapetane-1-sulfuric acid or DSS) in D2O was used as a reference for the proton 
chemical shifts. The NMR data were processed with NMRDraw to determine the peak positions 
and chemical shifts in the 
1
H-
15
N HSQC spectra. 
 
2.7. Binding studies of 
15
N-labeled EC1 protein with cyclic ADTC7, ADTC9 and HAVc3 peptides 
 The 
15
N-labeled EC1 protein (0.18 mM) was titrated with 0.4 mM stock of ADTC7 peptide 
at protein/peptide ratios of 1:0.2, 1:0.4, 1:0.8, 1:1, 1:2, 1:3, 1:4, 1:5, 1:8, 1:10; 1:15, and 1:21. 
For the ADTC9 peptide, 0.4 mM 
15
N-labeled EC1 protein was titrated with 2.0 mM stock of 
peptide at protein/peptide ratios of 1:0.2, 1:0.4, 1:0.8, 1:1, 1:2, 1:3, 1:4, 1:6, 1:8, 1:10; 1:15, and 
1:20. Finally, 0.4 mM of the 
15
N-labeled EC1 protein was titrated with 2.0 mM of cyclic HAVc3 
peptide at protein/peptide ratios of 1:1, 1:4, and 1:8. The overall shift (ΔF) after titration was the 
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combined changes between 
1
H and 
15
N chemical shifts; this shift was calculated using the 
following equation:   ΔF = [(Δδ1H*599.743)2+(Δδ15N*60.778)2]. 
 
2.8. Molecular docking experiments with Autodock Vina: 
Molecular docking experiments were performed using Autodock Vina programs (Vina, The 
Scripps Institute) [30]. The EC1 domain structure used for the molecular docking experiments 
was derived from the X-ray structure of domain-1 and -2 of human E-cadherin acquired from the 
RCSB Protein Data Bank (entry code 2O72). While maintaining the same interface region, 
Discovery Studio Visualizer 2.5 program was used to remove water molecules and generate the 
EC1 domain model. The 3D structures of the peptides (i.e., ADTC5, ADTC7, ADTC9, and 
HAVc3) were generated using InsightII Program (Accelrys, Inc., San Diego, CA) and their 
conformations were optimized by energy minimization using CVFF91 force field. The final 
receptor and ligand coordinates were saved as protein data bank (pdb) files. After uploading 
these files into Autodock, AutodockTools were used to add partial charges and arrange the polar 
hydrogen in the protein. While maintaining the protein as a rigid structure, the ligands were set to 
have flexible torsion angles at all rotatable bonds. Using affinity energy (kcal/mol) and a root-
mean-square deviation (RMSD) of 2.0, the interaction between peptide and EC1 was scored and 
ranked to generate potential binding sites. 
 
3. Results and Discussion 
 
3.1. Expression and purification of the EC1 domain  
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Expression and purification of the non-labeled and 
15
N-labeled EC1 domain were 
accomplished without any problems. Figure 1 shows one band on the SDS-PAGE for purified 
non-labeled and 
15
N-labeled EC1 protein with a molecular weight of 18 KDa for EC1. The 
expressed EC1 domain has 150 amino acids of which (a) the first 13 amino acids at the N-
terminus contain the MWSHPQFEKIEGR sequence for recognition by StrepTactin II affinity 
column, (2) the middle 110 amino acids are from the original sequence of the EC1 domain, and 
(c) the last 28 amino acids are from the interface region between the EC1 and EC2 domains 
(Figure 2).  
The 
1
H,
15
N-HSQC 2D-NMR spectra of the EC1 domain showed a good dispersion of 
crosspeaks from the amide groups, indicating the folded protein (Figure 2) [31]. The assignments 
of almost all of the residues have been completed; a few residues cannot be assigned due to 
overlapping resonances [29]. The residue assignments were used to evaluate the binding site(s) 
of peptide on the EC1 domain.  
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Figure 1. SDS-PAGE of the purified (A) 
15
N-labled EC1 domain and (B) non-labeled EC1 
domain of human E-cadherin after affinity column chromatography using a StrepTactin II 
column. The pure protein was run with the molecular weight marker molecules and the EC1 
protein showed a molecular weight of 18 KDa. 
  
EC
EC
18 KDa 
18 KDa 
A B 
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Figure 2. The amino acid sequence of the EC1 domain of human E-cadherin. The bold blue 
region is the tag sequence used for affinity purification of EC1 with a Strep-Tactin II affinity 
column. The black sequences are the 110 original amino acids for EC1. The green section is the 
sequence of the interface between the EC1 and EC2 domains. Most of the secondary structures in 
EC1 are beta sheets with one alpha helix. The sequences marked with red rectangles have beta-
sheet secondary structure, and the one marked with a green cylinder shows the alpha-helix 
structure.   
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Figure 3. 
1
H,
15
N-HSQC 2D-NMR spectrum of the EC1 domain in 600 MHz NMR. The protein 
was dialyzed in 20 mM KH2PO4 and 5 mM DTT buffer at pH 6.0, and 6% D2O was added to 470 
μL of 
15
N-labeled EC1 sample. 
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Figure 4.  Effect of titration of ADTC7 peptide on the 
1
H,
15
N-HSQC 2D-NMR spectra of the 
EC1 domain observed using 600 MHz NMR. The protein (0.18 mM) was dissolved in 20 mM 
KH2PO4 and 5 mM DTT buffer at pH 6.0. The spectrum of the protein alone is shown in black 
and the spectrum of the peptide-titrated protein (protein/peptide ratio = 1:15) is in blue. The data 
show the maximum changes in chemical shifts (F) for residues that are affected by peptide 
addition. 
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3.2. Studies of binding of ADTC7 to the EC1 domain 
3.2.1 NMR binding studies 
The binding site(s) of ADTC7 to the EC1 domain were evaluated using 
1
H,
15
N-HSQC 2D-
NMR spectroscopy by titrating the protein with increasing concentrations of ADTC7 peptide 
with protein/peptide ratios between 1:0.2 and 1:20 (Figure 4). The crosspeaks shown in black are 
from the protein alone and the blue crosspeaks are from the protein titrated with the peptide. 
Upon titration with ADTC7, the NH crosspeaks were shifted with overall chemical shift changes 
in residues that have a high probability of binding to the peptide. These shifted crosspeaks were 
from the NH resonances of Ile4, Leu21, Ile38, Val48, Ile53, Thr97, Val98, Asp103, Phe113, 
Gly115, Glu119, Ala132, and Thr133 (Figure 5). These residues are from three different regions 
or sites of the EC1 domain and its C-terminal tail domain. 
The magnitudes of changes at protein/peptide ratios of 1:4 and 1:8 are plotted in Figure 5. 
For EC1 titration with ADTC7, the NH crosspeaks of the Val48, Ile53, Asp103, and Gly115 
residues in EC1 have large changes, suggesting that these residues are involved in the binding 
process between EC1 and ADTC7 peptide. Because these residues are located in different parts 
of EC1, an alternative explanation is that some residues that have shifted crosspeaks may be 
directly or indirectly involved in the binding process. In other words, the chemical shift changes 
may be due to conformational changes at the particular region of EC1. Therefore, there are 
several possible explanations for the changes in the chemical shifts at three different parts of the 
EC1 protein upon peptide addition. First, the peptide can bind to three different regions of the 
protein with similar or different binding affinities. Second, the peptide can bind to two regions of 
the protein that caused conformational changes in the third region of the protein, resulting in 
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chemical shift changes in the third region. Third, the peptide can bind to one site of the protein, 
resulting in conformational changes at two other regions of the protein and causing chemical 
shift changes in these remote sites or regions. At this time, the assumption is that any chemical 
shift change is due to binding between the peptide and the residue in different binding sites.  
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Figure 5. The overall chemical shift changes (F) for several residues in the EC1 domain after 
addition of peptides at  (A) protein/peptide ratio = 1:8 and (B) protein/peptide ratio = 1:4. For 
ADTC7 and ADTC9, the biggest shifts were on residues Gly115 and Val48. For HAVc3, the 
biggest change was on Asp103 and the second biggest change was on the Ile4 residue on the 
EC1 domain protein.  
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Figure 6. The effect of titration of different concentrations of ADTC7 peptide on the overall 
chemical shifts of (A) Ile53, (B) Asp103, (C) Val48, and (D) Gly115 residues on the EC1 
domain. The peptide titration curves show binding saturation. The estimated Kd for ADTC7 
binding to EC1 are (A) 64.35 μM (R
2
 = 0.97) and (B) 66.68 μM (R
2
 = 0.98) for Asp103, (C) 137 
μM (R
2
 = 0.99) for Val48, and (D) 162 μM (R
2
 = 0.96) for Gly115. 
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To evaluate the tightness of binding of ADTC7 at different sites of EC1, the titration data 
were plotted to estimate the peptide dissociation constants at different sites of EC1. There are at 
least three potential binding constants of ADTC7 to EC1 domain. The first saturation curve was 
found at a protein/peptide ratio of 1:2, and the second saturation curve was at a protein peptide 
ratio of 1:7 on some residues of EC1. The first group of estimated dissociation constants (Kd) for 
binding are around 64.35 μM and 66.68 μM as reflected in the Ile53 (Fig. 6A) and Asp103 (Fig. 
6B) residues, respectively. The second group of dissociation constants are around 136–142 μM, 
which are in the titration curves of Ile4, Val48, Thr97, and Val98 (Table 2). The third group of 
dissociation constants found were from Phe113 (Kd = 150 μM), Thr133 (Kd = 150 μM), and 
Gly115 (Kd = 162 μM). These results suggest that the ADTC7 peptides could bind to three 
different regions of EC1 with different affinities. 
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Table 2. The Kd calculated from different residues in EC1 
after titration with ADTC7 and ADTC9 peptides 
 Kd (μM) 
Residue ADTC7 ADTC9 
I4 142 403 
L21 239.76(263.34) 181.81 
I38 96.34(200.86) - 
V48 137 658 
I53 64.35 218(464) 
T97 136 1075 
V98 137 965 
D103 66.68(148) 450.21 
F113 150 1031 
G115 162 1023 
E119 627 961 
T133 150 814 
 
Table 3. The chemical shift changes of residues in the EC1 domain upon addition of 
ADTC7 and ADTC9 peptides at a protein/peptide ratio of 1:8 
 F (1:8) 
Residue ADTC7 ADTC9 Cyclic HAVc3 
I4 3.97 5.33 11.18 
L21 7.78 11.02 5.35 
I38 16.70 - 9.87 
V48 13.03 13.59 9.36 
I53 12.21 13.10 7.1 
T97 12.46 7.33 1.84 
V98 8.27 5.57 9.36 
D103 18.57 6.50 49.95 
F113 10.21 5.06 5.96 
G115 17.1 15.56 3.63 
E119 7.22 7.54 0.91 
T133 9.44 7.87 3.8 
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Figure 7. The results of docking experiments between ADTC7 and the EC1 domain and the tail 
region. (A) Four potential binding sites for ADTC7 on the EC1 domain were found. (B) Three 
potential binding sites of ADTC7 were found on the tail region of EC1.  
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3.2.2. Molecular docking of ADTC7 on EC1 
To evaluate potential binding sites of ADTC7 on the EC1 domain, molecular docking studies 
were carried out using the Autodock Vina program. In this study, the ADTC7 structure was built 
using the molecular modeling program Insight, and the peptide conformation was minimized 
using a Discover program. The coordinates of the peptides were converted to protein data bank 
(pdb) coordinates for molecular docking experiments. The coordinate for the EC1 domain was 
derived from the X-ray structure of EC1-2 domain of E-cadherin. Similar to the expressed EC1 
domain, the model for EC1 domain contains the interface region between EC1 and EC2 domain, 
which is called the C-terminal tail region or tail region. The first and second docking 
experiments were done to search for peptide binding regions on the main EC1 structure and the 
C-terminal tail region, respectively.  
Docking of ADTC7 to the main EC1 domain shows that the peptide binds to four different 
regions of EC1: the N-terminal, Leu21, Ile53, and Asp103 (Figure 7A). There are three potential 
binding sites for the tail region; the peptide can bind to Asp103/Thr133, Phe113/Gly115, and 
Glu119 (Figure 7B). The docking model of ADTC7 at Ile53 in the main EC1 was supported by 
the large chemical shift change of Ile53 (Figures 4 and 5) and the low Kd (64 M, Figure 6A). 
The peptide docking at Ile53 also involves interactions with Ile38 and Val48, and the calculated 
Kd using Ile38 and Val48 chemical shift changes are 96 M and 137 M, respectively. This 
result suggests that Ile38 and Val48 have weaker interactions with ADTC7 than does Ile53. 
There are several docking conformations in the Ile53 binding site with docking energies of –6.3, 
–6.1, and –6.0 kcal/mol.  
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The second favorable binding site of ADTC7 is at the Asp103 in the EC1 domain, which is 
supported by the larger chemical shift changes of the Asp103 residue during peptide titration 
(Figure 5, Table 3). The peptide docked at this site also binds to Thr133 residue. Binding to this 
site is predicted to also change the conformation at the Thr97 and Val 98 residues. Binding at the 
Asp103 site is also supported by the low Kd (66.68 M) seen in the titration study. The 
involvements of Thr133, Thr97, and Val98 are supported by their Kd at 150 M, 136 M, and 
137 M, respectively (Table 2). These values are higher than the Kd of Asp103, suggesting that 
they have a secondary role during binding at the Asp103 site. 
The third possible binding model is peptide binding at the Phe113 and Gly115 residues of the 
tail region (Figure 7B). Upon titration with peptides, the NHs of Phe113 and Gly115 have large 
chemical shift changes. This binding site is less likely to be the primary binding site because the 
calculated Kd for binding to Phe113 and Gly115 are 150 M and 162 M. It is proposed that the 
tail region can be folded into the main EC1 domain upon binding to the peptide; thus, peptide 
binding to Phe113 and Gly115 can be the result of a secondary event in which a peptide binding 
to a primary site (i.e., Asp103) on the EC1 domain followed by folding of the tail region (Phe113 
and Gly115) into the main region of EC1 around Asp103. Molecular dynamics simulations 
studies are being carried out to test this hypothesis. 
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Figure 8. 
1
H,
15
N-HSQC 2D-NMR spectra of EC1 titrated with ADTC9 peptide observed using 
600 MHz NMR. The protein was dissolved in 20 mM KH2PO4 and 5 mM DTT buffer at pH 6.0 
at 0.4 mM concentration. The spectrum of the protein is in purple and the spectrum of the 
peptide-titrated protein is pink; the protein/peptide ratio is 1:15. The data show the maximum 
change in chemical shifts (ΔF) for residues that are affected. 
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3.3. Binding studies of ADTC9 to the EC1 domain 
3.3.1 NMR binding studies 
The EC1 domain was also titrated with ADTC9 peptide at protein/peptide ratios of 1:0.2 to 
1:20, and the chemical shift changes (F) were followed in various residues (Figures 5 and 8, 
Table 3). The greatest change was observed in the chemical shift of residues Leu21, Val48, 
Ile53, and Gly115. In contrast to ADTC7, ADTC9 did not cause a dramatic change in the 
chemical shift of Asp103; this is presumably due to mutation of the Glu6 residue in ADTC7 to 
the Tyr6 residue in ADTC9 (Table 3). The lowest Kd of binding of ADTC9 were found at Leu21 
(181.81 M) followed by Ile53 (218 M). The titration curves for Leu21 and Ile53 have two 
saturation regions (i.e., at low and high peptide concentrations), suggesting the possibility of two 
binding sites. Unlike ADTC7, the calculated Kd at the Asp103 residue is  high (450 M), 
suggesting that the Asp103 residue is not a favorable binding site for ADTC9. Furthermore, the 
Kd for Thr133 was 814 mM, which is very high compared to that of Thr133 (150 M) for 
ADTC7 titration. Although the chemical shift changes were high for Gly115 when titrated with 
ADTC9, the Kd of Gly115 was very high (1023 M), as were those of Phe113 (1031 M) and 
Glu119 (961 M). In summary, ADTC9 has two potential binding sites on the EC1 domain with 
dissociation constants of 181–218 mM at Leu21 and 403–450 mM at Ile53.  
 
3.3.2. Molecular docking of ADTC9 on EC1 
Molecular docking experiments showed that ADTC9 peptide has two binding sites on the 
main EC1 domain (Figure 9). One binding site is at the Ile53 residue and the other binding site is 
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at the N-terminal of EC1 around the Trp2 residue. Although the NMR data suggest that the 
Leu21 has the lowest Kd of binding, no ADTC9 was found docked at the Leu21 site on EC1. 
Thus, further studies are needed for evaluating the potential binding of ADTC9 at the Leu21 site 
on EC1. In contrast to ADTC7, ADTC9 does not bind to the tail region of EC1 nor does it 
interact with Gly115. Instead, the docking experiment suggests that ADTC9 interacts at another 
part of the tail region (i.e., Ala132, Asp134, Thr133 and Glu129). 
 
 
Figure 9. Molecular docking of ADTC9 to the EC1 domain. The two possible binding sites of 
ADTC9 on the main EC1 domain. The first binding site invoves the Ile38, Ile53, and V48 
residues, and the second involves the N-terminus of the EC1 domain.  The second binding 
domain involved the Trp2 residue at the N-terminus. 
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3.4. Binding studies of HAVc3 to the EC1 domain 
3.4.1 NMR binding studies 
Similar to ADTC7 and ADTC9, the EC1 domain was titrated with different concentrations of 
HAVc3, and the chemical shift changes were observed in 
1
H, 
15
N-HSQC 2D-NMR spectra 
(Figure 10). The largest chemical shift change (ΔF) was found at the Asp103 residue (Figures 5 
and 10 and Table 3). The second biggest chemical shift changes were found at the Ile4 residue 
and the Ile38 residue. The chemical shift changes in Leu21 and Gly115 upon titration with 
HAVc3 were much lower than those produced by titration with ADTC7, suggesting that HAVc3 
binds at different sites than ADTC7. The effects of peptide concentrations on the chemical shift 
changes are shown in Figure 11. Due to a limited number of titration concentrations, it was 
difficult to determine the Kd at affected residues on the EC1 domain. Because of the large 
change in the Asp103 chemical shift compared to those of other residues, the result suggests that 
HAVc3 selectively binds around the Asp103 residue and not to other residues or sites.  This also 
suggests that HAVc3 has only one binding site at the EC1 domain.  
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Figure 10. 
1
H,
15
N- HSQC 2D-NMR spectra of EC1 titrated with cyclic HAVc3 peptide 
using 600 MHz NMR. The protein was dissolved in 20 mM KH2PO4 and 5 mM DTT buffer 
at pH 6.0 at 0.4 mM concentration. The spectrum of the protein is in black and the spectrum 
of peptide-titrated protein is red; the protein/peptide ratio is 1:8. The data show the maximum 
change in chemical shifts (ΔF) for residues that are affected. 
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Figure 11. Binding curves for different residues of EC1 titrated to the HAVc3 peptide. The 
chemical shift of Asp103 shows large changes upon saturation at the 1:1 ratio, while other 
residues show low chemical shift changes. 
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4. Conclusion 
The NMR studies indicate that ADTC7, ADTC9 and HAVc3 bind to the EC1 domain of E-
cadherin. The ADTC7 has higher binding properties than ADTC9. The NMR data indicate that 
ADTC7 and ADTC9 have favorable binding sites at the Ile53 and Leu21 residues. ADTC7 has 
an additional binding site at the Asp103 residue while ADTC9 does not. The NMR data show 
that HAVc3 binds selectively to the Asp103 residue in EC1. The docking experiments suggested 
that ADTC7 and ADTC9 bind favorably to the Ile53 sites at the EC1 domain. In the future, more 
detailed NMR titration studies will be carried out on HAVc3 peptide at concentrations between 
protein/peptide ratios from 1:0.2 to 1:3. These studies are an attempt to increase the number of 
data points for Kd determination.  The docking experiments will also be carried out for the 
HAVc3 peptide. Finally, molecular dynamics simulation studies will be initiated to evaluate the 
effects of peptide binding on the conformational changes in the EC1 domain, especially the 
effect of peptide binding on the folding of the tail region of EC1.  
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